Advertisements
Synthesis of Arylpiperazines as Perspective Toxoplasma gondii Dihydrofolate Reductase Inhibitors
| Price: | US$ 1 / Gram |
|---|---|
| Minimum Order: | |
| Payment Terms: | T/T |
| Port of Export: |
Product Details
| Model No.: | Brand Name: |
|---|
| Certification: | |
|---|---|
| Specification: | Synthesis of high-quality small organic compounds for HTS, chemical building blocks and intermediates |
Packaging & Delivery
| Packaging: | |
|---|---|
| Delivery/Lead Time: | |
| Production Capacity: |
Product Description
Toxoplasmosis is a parasitic disease caused by Toxoplasma gondii. Approximately one-third of the population worldwide is chronically infected with T. gondii. First-line treatment of toxoplasmosis is a therapy based on dihydrofolate reductase (DHFR, DHFRP1, DYR) inhibitors which act on the folate metabolic pathway, thereby inhibiting T. gondii proliferation and survival. Our company offers the chemical optimization service - synthesis of a unique DHFR targeted set of novel arylpiperazine derivatives for your biological projects, related to developing of anti-toxoplasmosis drugs. These novel compounds could be selected from a set of 1,000+ exclusive virtual arylpiperazines using our company’s proprietary molecular modeling platform ODDA™.
This target-specific set of novel arylpiperazine derivatives will be synthesized exclusively upon your request.
A recent paper from the Journal of Medicinal Chemistry* showed that authors synthesized a series of arylpiperazines through structural modification of TRC-19 (a lead compound from their previous study, IC50 = 8.76 nM).
|
SUPPLIER PROFILE
|
|||
|---|---|---|---|
| Company: | Otava Institute | ||
| City/State | Kyiv, | Country: |
Ukraine 
|
| Business Type: | Other Trade Services | Established: | NA |
| Member Since: | 2018 | Contact Person | Nadiia Kapachut |
SUPPLIER PROFILE
City/State/Country -
Kyiv,
Ukraine
Business Type -
Other Trade Services
Established -
NA
Member Since -
2018
Contact Person -
Nadiia Kapachut